In RB1-deficient CRPC and NEPC, DNMTi leads to increased expression of B7-H3, and using B7-H3 targeted ADC in combination with DNMTs leads to tumor regression in preclinical models (Yamada et al, 2023). This evidence concerns the gene CD276 and neoplasm.